Proposed Article Structure
For this topic, a clinically appropriate structure includes: Highlights; Clinical Background and Unmet Need; Study Design and Methods; Key Results; Safety and Adverse Events; Clinical Interpretation; Registry-Based Device Evaluation and Regulatory Implications; Limitations; Conclusion; Funding and ClinicalTrials.gov; References.
Highlights
The EXCOR Active Driver was prospectively evaluated across multiple U.S. centers in pediatric patients requiring Berlin Heart EXCOR support, a population with substantial clinical complexity and limited device options.
No major device malfunctions were reported in either the 40-patient investigational device exemption cohort or the 118-patient continued access cohort, supporting strong technical reliability.
Among investigational device exemption patients, 90-day mortality was 0%, stroke incidence was 12.5%, and most patients were either alive on support or had transitioned to transplantation, recovery, or another support strategy.
The study also offers an important proof of concept for using registry-enabled infrastructure to evaluate high-risk class III pediatric devices more efficiently.
Clinical Background and Unmet Need
Durable mechanical circulatory support in children remains one of the most challenging areas in advanced heart failure care. Pediatric patients with end-stage heart failure often require ventricular assist devices as a bridge to transplantation, a bridge to recovery, or a bridge to decision-making. Yet unlike adult practice, where several implantable continuous-flow options are available, support choices for infants and small children are far more limited.
The Berlin Heart EXCOR Pediatric has filled a critical gap as the only durable ventricular assist device specifically approved for smaller children and infants. Its clinical importance is well established, particularly for patients who are too small for adult-sized intracorporeal systems. However, the system’s external driving platform has historically imposed meaningful restrictions. The traditional IKUS driver is relatively bulky, reducing patient mobility and creating major barriers to rehabilitation, discharge readiness, and quality of life. For children facing prolonged waiting times to transplant, these limitations are not trivial; they affect neurodevelopment, physical conditioning, caregiver burden, and hospital resource utilization.
The EXCOR Active Driver was developed to address these practical shortcomings. Its intended advantages include improved portability, longer battery life, and more physiologic pumping adaptability. In principle, a more mobile and responsive driver could support ambulation, rehabilitation, and potentially broader use beyond the intensive care environment. The current study therefore evaluates not merely a technical upgrade, but a clinically meaningful redesign aimed at making long-duration pediatric support more compatible with daily life.
Study Design and Methods
Edelson and colleagues conducted a prospective, multicenter clinical trial under a U.S. Food and Drug Administration-approved investigational device exemption, followed by a continued access protocol. This design is important because it combines a formal prospective evaluation with an expanded real-world cohort after initial regulatory experience, thereby allowing assessment of both device performance and practical implementation.
The investigational device exemption cohort included 40 subjects. The mean age was 38.2 months, underscoring the very young nature of the population. Notably, 55% had congenital heart disease, a subgroup often underrepresented in conventional device studies and one in whom support strategies are especially complex because of anatomic heterogeneity, prior surgeries, and altered hemodynamics.
After the initial cohort, 118 additional patients were enrolled through a continued access protocol. Together, these cohorts provide information on device behavior in a high-risk and clinically diverse pediatric population.
The primary endpoints included major device malfunction, adverse events, and successful outcomes. Successful outcomes were defined pragmatically as survival to transplantation, recovery, or continued support at 90 days postimplantation. This is a reasonable composite in pediatric mechanical support studies, where many children remain on device at prespecified time points while awaiting donor organs.
Adverse events were adjudicated by an independent Clinical Events Committee, and a Data Safety Monitoring Board provided oversight. These design features strengthen the credibility of the safety data. Outcomes were analyzed using descriptive statistics and competing risk models, an appropriate approach because transplantation, recovery, conversion to another support modality, and death are mutually competing outcomes in this setting.
Key Results
Investigational Device Exemption Cohort
Among the 40 patients enrolled under the investigational device exemption, there were no episodes of major device malfunction. This finding is central to the study and directly addresses the primary engineering and regulatory concern for a new driver platform.
At 90 days, 65% of patients remained on support. An additional 17.5% had undergone transplantation, 15.0% had been converted to another support modality, and 1 patient was explanted for recovery. Importantly, the 90-day mortality rate was 0%.
These outcomes suggest that the driver was able to sustain support effectively through the early high-risk period after implantation. The large proportion still on support at 90 days is consistent with pediatric transplant wait-list realities rather than a sign of treatment failure. In fact, continued survival on support is often the intended therapeutic state until a suitable donor becomes available.
Continued Access Protocol Cohort
The larger continued access cohort of 118 patients also experienced no major device malfunctions. At the time of data abstraction, 37% had undergone transplantation, 31% were alive on device, 6% had device explant for recovery, and 23% had been converted to another support modality. Three patients had withdrawal of support. Survival at 90 days was 98.1%.
These figures are clinically reassuring. They suggest that performance observed in the initial prospective cohort translated into broader real-world use without emergence of new reliability concerns. Recovery remained uncommon but present, which is expected in pediatric severe heart failure populations where durable support is frequently used as a bridge to transplant rather than bridge to recovery.
How Should These Results Be Interpreted?
The most striking result is the absence of major device malfunctions across both cohorts. In pediatric circulatory support, hardware reliability is not a secondary issue; it is a determinant of survival. The patient population is small, fragile, and often managed for prolonged durations. Any reduction in catastrophic driver-related failure risk has immediate clinical relevance.
The survival data are also encouraging, especially given the complexity of the cohort and the high proportion with congenital heart disease. While the study does not compare the Active Driver directly against the IKUS driver, the observed outcomes appear consistent with continued feasibility of EXCOR support while potentially removing one of the most burdensome aspects of care: the limitations imposed by a less mobile driving system.
Safety and Adverse Events
Stroke occurred in 12.5% of patients in the investigational device exemption cohort. This remains a major concern in pediatric VAD care and requires careful interpretation. The study’s main safety success relates to device reliability rather than elimination of thromboembolic risk. Neurologic events are multifactorial in children supported with paracorporeal pulsatile devices and may reflect patient-specific factors, cannulation strategy, underlying diagnosis, anticoagulation management, infection, inflammatory activation, and duration of support, rather than driver mechanics alone.
Even so, a stroke rate in this range reminds clinicians that advances in mobility and driver design do not remove the need for intensive neurologic surveillance and rigorous anticoagulation protocols. Historically, stroke has been one of the most serious complications associated with pediatric EXCOR support. Therefore, although the present study is a clear success from a device-function standpoint, it should not be interpreted as resolving the broader complication profile of pediatric VAD therapy.
The 0% 90-day mortality in the investigational device exemption group and 98.1% 90-day survival in the continued access population are highly favorable, but these outcomes should be viewed within the context of experienced centers, careful oversight, and selected patients eligible for EXCOR support. They are impressive real-world signals, though not necessarily generalizable to all institutions with varying levels of pediatric mechanical support expertise.
Clinical Interpretation
From a bedside perspective, the value of the Active Driver lies in what it may enable rather than only in what it avoids. A lighter, more mobile driving system may facilitate ambulation, participation in therapies, caregiver interaction, and potentially hospital discharge planning in selected children. These quality-of-life dimensions are especially important in pediatrics, where extended immobilization can impair developmental progress and place profound strain on families.
The study abstract emphasizes improved mobility, battery life, and physiologic adaptability, but it does not present detailed patient-reported, rehabilitation, or home-discharge outcomes. That absence does not diminish the engineering achievement, but it highlights the next important research step. If the Active Driver truly changes the lived experience of support, future reports should quantify endpoints such as days out of intensive care, ambulation milestones, participation in rehabilitation, discharge to home, caregiver burden, and health-related quality of life.
Another notable point is the inclusion of a large proportion of children with congenital heart disease. This matters because these patients often present the most difficult support decisions in pediatric advanced heart failure. If the Active Driver proves consistently useful across anatomically complex patients, its clinical impact could extend beyond a narrow transplant cardiomyopathy population.
Registry-Based Device Evaluation and Regulatory Implications
One of the study’s most important contributions may be methodological rather than purely clinical. The authors conclude that the trial validates the feasibility of leveraging a clinical registry infrastructure for class III device evaluation. For pediatric devices, this is potentially transformative.
Traditional large randomized trials are often impractical in pediatric mechanical circulatory support because eligible populations are small, disease phenotypes are heterogeneous, and urgent clinical need limits equipoise. A rigorous registry-based framework, with prospective enrollment, standardized endpoint definitions, independent event adjudication, and regulatory oversight, may provide a more scalable and cost-efficient pathway for evaluating high-risk pediatric devices.
This approach aligns with broader efforts in pediatric cardiology and rare disease research to generate high-quality evidence despite limited sample sizes. However, success depends on maintaining strong data completeness, consistent event definitions, and protection against bias. The present study appears to have incorporated key safeguards, including independent adjudication and monitoring.
Limitations
Several limitations should temper interpretation. First, the abstract does not describe a concurrent control group using the IKUS driver, so superiority cannot be formally established. The study demonstrates safety, reliability, and feasibility, but comparative effectiveness remains uncertain.
Second, the reported outcomes focus primarily on technical malfunction and broad clinical disposition endpoints. Detailed data on functional status, inpatient versus outpatient management, duration of support, neurodevelopmental outcomes, bleeding, infection, and anticoagulation-related complications are not available in the abstract.
Third, although the multicenter design enhances external validity, the experience likely reflects specialized pediatric heart failure and transplant centers. Results may not be immediately reproducible in lower-volume programs without equivalent infrastructure and expertise.
Fourth, the continued access cohort was summarized at the time of data abstraction rather than at a uniform follow-up interval for all endpoints. While common in post-approval or access-expansion settings, this can complicate direct comparison with the initial 90-day analysis.
Finally, because the article centers on the driver rather than the entire support ecosystem, it does not resolve longstanding challenges of pediatric VAD care, particularly neurologic events and the complexity of anticoagulation management.
Conclusion
This prospective multicenter evaluation supports the EXCOR Active Driver as a reliable advancement in pediatric ventricular assist device support. Across both the investigational device exemption and continued access cohorts, no major device malfunctions were observed, and short-term survival was excellent in a high-risk population that included many children with congenital heart disease.
The study’s practical significance is considerable. For children dependent on Berlin Heart EXCOR support, improved mobility and portability may represent a meaningful step toward more humane, developmentally appropriate care during prolonged bridging to transplant or recovery. Just as importantly, the trial offers a persuasive model for registry-enabled evaluation of class III pediatric devices, a strategy that may accelerate evidence generation in other rare but high-need populations.
The next phase of evidence should focus on whether the technical advantages of the Active Driver translate into measurable gains in rehabilitation, discharge readiness, caregiver burden, neurodevelopment, and long-term outcomes. For now, the findings provide strong reassurance that the new driver can deliver what matters most at baseline: dependable support without major device malfunction.
Funding and ClinicalTrials.gov
Funding information was not reported in the abstract provided. A ClinicalTrials.gov registration number was not listed in the abstract or citation details supplied here.
References
1. Edelson JB, O’Connor MJ, Shezad M, Duganiero T, Auerbach SR, Bleiweis M, Dykes JC, Joong A, Khan S, Law S, Mokshagundam D, Ploutz M, Raskin A, Su J, Tunuguntla H, VanderPluym C, Villa C, Rosenthal DN, Lorts A. Prospective Multicenter Evaluation of a Novel Active Driving System for Pediatric Ventricular Assist Device Support. Journal of the American College of Cardiology. 2026-04-28. PMID: 42089850.
2. Fraser CD Jr, Jaquiss RDB, Rosenthal DN, Humpl T, Canter CE, Blackstone EH, Naftel DC, Ichord RN, Bomgaars L, Tweddell JS, Massicotte MP, Turrentine MW, Cohen G, Almond CSD, Buchholz H, Goldstein B, Forbess J, Kroslowitz R, et al. Prospective trial of a pediatric ventricular assist device. N Engl J Med. 2012;367(6):532-541.
3. Rossano JW, Lorts A, VanderPluym C, Jeewa A, Franey LM, Blume ED, Almond CSD, Buchholz H, Rosenthal DN, Cantor RS, Conway J, Hollander SA, Lasa JJ, Tjossem C, Zampi JD, Dipchand AI. Outcomes of pediatric patients supported with continuous-flow ventricular assist devices: a report from the Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs). J Heart Lung Transplant. 2021;40(9):1003-1011.
4. Canter CE, Shaddy RE, Bernstein D, Hsu DT, Chrisant MRK, Kirklin JK, Canniffe C, Cohen G, Dipchand AI, Mahony L, et al. Indications for heart transplantation in pediatric heart disease: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young. Circulation. 2007;115(5):658-676.